Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Na.HO4P |
| Molecular Weight | 142.959 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].O[32P]([O-])([O-])=O
InChI
InChIKey=BNIILDVGGAEEIG-JCIGTKTHSA-L
InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2/i;;5+1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO4P |
| Molecular Weight | 96.9794 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
| Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:53 GMT 2025
by
admin
on
Mon Mar 31 18:05:53 GMT 2025
|
| Record UNII |
O181101B5G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129819
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
||
|
WHO-ATC |
V10XX01
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
||
|
NDF-RT |
N0000175872
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
||
|
WHO-VATC |
QV10XX01
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB76242
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
Sodium Phosphate P 32
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
527
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
5036
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
7635-46-3
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
71180
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL1060
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
DB09370
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
SUB04480MIG
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
C76284
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
O181101B5G
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
DTXSID30997712
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
100000137683
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | |||
|
91559
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
m10061
Created by
admin on Mon Mar 31 18:05:53 GMT 2025 , Edited by admin on Mon Mar 31 18:05:53 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |